Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications . Issue 11 (22nd September 2021)

• Record Type: Journal Article
• Authors: Gawałko, Monika; Agbaedeng, Thomas A; Saljic, Arnela; Müller, Dominik N; Wilck, Nicola; Schnabel, Renate; Penders, John; Rienstra, Michiel; van Gelder, Isabelle; Jespersen, Thomas; Schotten, Ulrich; Crijns, Harry J G M; Kalman, Jonathan M; Sanders, Prashanthan; Nattel, Stanley; Dobrev, Dobromir; Linz, Dominik
• Is Part Of: Cardiovascular research. Volume 118:Issue 11(2022)
• Page Start: 2415
• Page End: 2427
• Publication Date: 2021-09-22
• Subjects: Arrhythmia -- Atrial fibrillation -- Cardiometabolic -- Gut microbiota -- Metabolites; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Periodicals; 616.1
• DOI: 10.1093/cvr/cvab292
• Languages: English
• ISSNs: 0008-6363

Abstract

Abstract: Recent preclinical and observational cohort studies have implicated imbalances in gut microbiota composition as a contributor to atrial fibrillation (AF). The gut microbiota is a complex and dynamic ecosystem containing trillions of microorganisms, which produces bioactive metabolites influencing host health and disease development. In addition to host-specific determinants, lifestyle-related factors such as diet and drugs are important determinants of the gut microbiota composition. In this review, we discuss the evidence suggesting a potential bidirectional association between AF and gut microbiota, identifying gut microbiota-derived metabolites as possible regulators of the AF substrate. We summarize the effect of gut microbiota on the development and progression of AF risk factors, including heart failure, hypertension, obesity, and coronary artery disease. We also discuss the potential anti-arrhythmic effects of pharmacological and diet-induced modifications of gut microbiota composition, which may modulate and prevent the progression to AF. Finally, we highlight important gaps in knowledge and areas requiring future investigation. Although data supporting a direct relationship between gut microbiota and AF are very limited at the present time, emerging preclinical and clinical research dealing with mechanistic interactions between gut microbiota and AF is important as it may lead to new insights into AF pathophysiology and the discovery of novel therapeutic targets for AF. Graphical Abstract: